# Resource Summary Report

Generated by RRID on Jul 30, 2026

## PE/Cyanine7 anti-human CD38

RRID:AB_2561904
Type: Antibody

### Proper Citation

BioLegend Cat# 356608, RRID:AB_2561904

### Antibody Information

**URL:** http://antibodyregistry.org/AB_2561904

**Proper Citation:** BioLegend Cat# 356608, RRID:AB_2561904

**Target Antigen:** CD38

**Host Organism:** mouse

**Clonality:** monoclonal

**Comments:** Applications: FC

**Antibody Name:** PE/Cyanine7 anti-human CD38

**Description:** This monoclonal targets CD38

**Target Organism:** human

**Clone ID:** Clone HB-7

**Antibody ID:** AB_2561904

**Vendor:** BioLegend

**Catalog Number:** 356608

**Alternative Catalog Numbers:** 356607

**Record Creation Time:** 20250820T063431+0000

**Record Last Update:** 20250821T002715+0000

### Ratings and Alerts

No rating or validation information has been found for PE/Cyanine7 anti-human CD38.

No alerts have been found for PE/Cyanine7 anti-human CD38.

## Data and Source Information

**Source:** Antibody Registry

## Usage and Citation Metrics

We found 5 mentions in open access literature.

**Listed below are recent publications.** The full list is available at RRID .

Petrov L, et al. (2025) Rewired type I IFN signaling is linked to age-dependent differences in COVID-19. Cell reports. Medicine, 6(8), 102285.

Goulding J, et al. (2023) A chimeric antigen receptor uniquely recognizing MICA/B stress proteins provides an effective approach to target solid tumors. Med (New York, N.Y.), 4(7), 457.

Mirlekar B, et al. (2022) Balance between immunoregulatory B cells and plasma cells drives pancreatic tumor immunity. Cell reports. Medicine, 3(9), 100744.

Khoo NKH, et al. (2022) Differential immunogenicity of homologous versus heterologous boost in Ad26.COV2.S vaccine recipients. Med (New York, N.Y.), 3(2), 104.

Singh M, et al. (2020) Lymphoma Driver Mutations in the Pathogenic Evolution of an Iconic Human Autoantibody. Cell, 180(5), 878.